Inquiry Basket
With advanced technology and years of experience, BOC Sciences provides multiple ADCs cytotoxin with linkers products to support your ADCs development and research. We also provide the service in a customizable fashion to suit our customers' specific research goals. We are known to our customers as a professional and attentive partner who delivers quality results.
Comprehensive one-stop antibody-drug conjugate service platform
Large Stock
More than 1000+ high-purity products in inventory
Global Delivery
Warehouses in multiple cities to ensure fast delivery
mg to kg
Qualified facilities & equipment of cGMP laboratory
24/7 Technical Support
Strict process parameter control to ensure product quality
Antibody-drug Conjugate (ADC) is a chemotherapeutic drug with strong cytotoxicity, which has both the powerful lethality of small molecule drugs and the high targeting of pure monoclonal antibodies, so it has become a hot issue in the research and development of tumor targeted therapy. The targeting of ADC originates from antibody, and the toxicity originates from payload. After the antibody binds to the cancer cells surface antigen, it mediates ADC to enter cells through endocytosis and transports into lysosomes through the endosome. ADC linkers or antibodies in lysosomes degrade and release small molecule drugs, which further exert cytotoxicity and kill tumor cells.
Fig. 1. Overview of different linker/spacer strategies used for ADCs (Journal of Pharmaceutical Sciences, 2020, 109(1): 161-168).
The ADC production process mainly includes monoclonal antibody preparation, linker preparation, small molecule drug preparation, ADC conjugation, purification and finished product assembly, which leads to the complexity of the production process and makes its structure analysis, design and manufacture face great challenges. As a complex entity that combines biological and chemical drugs, a single dimension elevation does not mean that the overall effect of drugs can be improved, and it needs to be considered comprehensively from a systematic perspective. Therefore, the ADC drugs development in addition to the selection of linkers and cytotoxins, one of the cores is the combination of linkers and cytotoxins. Considering that the antibodies of ADC drugs are infinite, the linkers, cytotoxins and conjugation methods are limited, ADCs cytotoxin with linkers compounds are often patented by pharmaceutical companies as core elements.
Based on the importance of the combination of linkers and cytotoxins, the conjugation method of antibody, inker and cytotoxin is also an important factor affecting the uniformity of ADC drugs and drug antibody ratio (DAR). Less cytotoxin will reduce the biological activity and efficacy of ADC drugs. Excessive cytotoxin will increase the ADC clearance rate in blood, and affects the antigen and antibody combination effective. Generally, the ideal DAR is 2-4. At present, the conjugation methods used for ADC drugs in clinical practice are mainly divided into random conjugation and site-specific conjugation. As a one-stop platform for ADC drug development, BOC Sciences offers a variety of antibody modification and conjugation technologies to facilitate your ADC drug research, ranging from carbohydrate conjugation, cysteine conjugation, lysine conjugation, unnatural amino acids conjugation and enzyme-modified antibody conjugation.
References
